Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Market price (% of par)
-
93.26%
-
Total 13F principal
-
$372,201,000
-
Principal change
-
-$33,653,000
-
Total reported market value
-
$347,788,000
-
Number of holders
-
40
-
Value change
-
-$28,762,418
-
Number of buys
-
18
-
Number of sells
-
22
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q1 2017
As of 31 Mar 2017,
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 was held by
40 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$372,201,000
in principal (par value) of the bond.
The largest 10 bondholders included
HIGHFIELDS CAPITAL MANAGEMENT LP, CITADEL ADVISORS LLC, DEERFIELD MANAGEMENT CO, WOLVERINE ASSET MANAGEMENT LLC, AMERIPRISE FINANCIAL INC, MACKAY SHIELDS LLC, Polar Capital LLP, LINDEN ADVISORS LP, SILVERBACK ASSET MANAGEMENT LLC, and LAZARD ASSET MANAGEMENT LLC.
This page lists
40
institutional bondholders reporting positions
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.